Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Daiichi Sankyo Company, Limited    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Daiichi Sankyo : Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/06/2019 | 09:01am EST

Tokyo - Daiichi Sankyo Co., Ltd announced today that the company has filed a Declaratory Judgement action in the District Court of Delaware in response to receiving communications from Seattle Genetics, Inc. with respect to a collaboration between the two companies from 2008 to 2015 for the development of antibody-drug conjugates (ADCs).

Seattle Genetics is claiming certain intellectual property rights related to Daiichi Sankyo's ADC products. Daiichi Sankyo believes any such claim to be without merit and the company will vigorously defend its position that our ADC technology patents are the exclusive intellectual property of Daiichi Sankyo.

Between July 2008 and June 2015, Seattle Genetics and Daiichi Sankyo collaborated in an exclusive, worldwide development agreement focused on ADCs which are distinct from ADC products currently being developed in the Daiichi Sankyo pipeline.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a 'Global Pharma Innovator with Competitive Advantage in Oncology,' Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

Contact:

Tel: +1 908 992 6633

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
DAIICHI SANKYO COMPANY, LIMITED 2.61% 7553 End-of-day quote.5.61%
SEATTLE GENETICS, INC. -1.54% 113.57 Delayed Quote.0.95%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
01/22Roche wins approval for cancer drug Kadcyla in fast-growing China market
RE
01/07DAIICHI SANKYO : ENHERTU Now Available in U.S. for HER2 Positive Unresectable or..
AQ
2019AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
RE
2019DAIICHI SANKYO : AstraZeneca - Enhertu approved in the US for HER2-positive unre..
AQ
2019DAIICHI SANKYO : ENHERTU Approved in the U.S. for HER2 Positive Unresectable or ..
AQ
2019DAIICHI SANKYO : Enhertu (trastuzumab deruxtecan) approved in the US for HER2-po..
AQ
2019DAIICHI SANKYO : Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous..
AQ
2019ASTRAZENECA : Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in..
AQ
2019Nikkei bounces back on trade deal hopes, steelmakers shine
RE
2019DAIICHI SANKYO : Announces Positive Results from ESAX-DN Phase 3 study in Japan ..
AQ
More news
Financials (JPY)
Sales 2020 967 B
EBIT 2020 129 B
Net income 2020 96 004 M
Finance 2020 337 B
Yield 2020 0,93%
P/E ratio 2020 50,8x
P/E ratio 2021 57,0x
EV / Sales2020 4,71x
EV / Sales2021 4,54x
Capitalization 4 894 B
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 7 892,31  JPY
Last Close Price 7 553,00  JPY
Spread / Highest target 32,4%
Spread / Average Target 4,49%
Spread / Lowest Target -27,2%
EPS Revisions
Managers
NameTitle
Sunao Manabe President, CEO & Representative Director
Joji Nakayama Chairman
Toshiaki Sai CFO, Representative Director & Executive VP
Wataru Takasaki Executive Officer, GM-Research & Development
Toshiaki Tojo Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED5.61%43 645
JOHNSON & JOHNSON1.82%390 912
ROCHE HOLDING AG4.27%288 339
MERCK AND COMPANY-1.43%225 472
PFIZER3.91%225 294
NOVARTIS-0.09%214 482